Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Non-Current Assets (2020 - 2025)

Foghorn Therapeutics has reported Non-Current Assets over the past 6 years, most recently at $34.9 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $34.9 million for Q4 2025, up 1.42% from a year ago — trailing twelve months through Dec 2025 was $111.4 million (down 27.66% YoY), and the annual figure for FY2025 was $34.9 million, up 1.42%.
  • Non-Current Assets for Q4 2025 was $34.9 million at Foghorn Therapeutics, up from $20.8 million in the prior quarter.
  • Over the last five years, Non-Current Assets for FHTX hit a ceiling of $64.6 million in Q1 2021 and a floor of $20.8 million in Q3 2025.
  • Median Non-Current Assets over the past 5 years was $48.5 million (2023), compared with a mean of $46.8 million.
  • Peak annual rise in Non-Current Assets hit 1.42% in 2025, while the deepest fall reached 43.87% in 2025.
  • Foghorn Therapeutics' Non-Current Assets stood at $60.2 million in 2021, then decreased by 11.17% to $53.5 million in 2022, then fell by 14.49% to $45.7 million in 2023, then fell by 24.83% to $34.4 million in 2024, then increased by 1.42% to $34.9 million in 2025.
  • The last three reported values for Non-Current Assets were $34.9 million (Q4 2025), $20.8 million (Q3 2025), and $22.4 million (Q2 2025) per Business Quant data.